Hot Investor Mandate: Asia-Based Investment Firm With $1B+ AUM Invests Around $5M and More Into Early Clinical Stage Projects, With Strong Interests in Therapeutics and Digital Therapeutics

2 Mar

An investment firm headquartered in Asia manages over $1.2B AUM and makes initial investments generally around $5M, but has the capacity to invest much higher amounts depending on the opportunity and fit. While the firm’s focus is on more developed companies, the firm is actively seeking early-stage opportunities with strong global potential, and is open to considering those outside of their headquarters.

Within life sciences, the firm’s main focus is in therapeutics and digital therapeutics, but the firm is also interested in medical devices, diagnostics, and digital health/healthcare IT. The firm looks at all modalities and indications. When considering therapeutics companies, the firm prefers to invest in early clinical stage projects and tend to avoid investing in pre-clinical ones.

The firm has no specific company or management team requirements. The firm can act as either a lead or co-investor, and will seek board representation in companies they fund as a lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: